Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy.

For both endpoints, higher gene expression of CSMD1 tended to be associated with better prognosis, although both log-rank p-values and univariable Cox regression analysis did not reach statistical significance (Fig. 7 E & F).

also in 111,027 other papers

However, our in vitro observations were further supported by the clinical data from a real-world RNA sequenced cohort, SCAN-B, where CSDM1 expression showed a trend towards better responses of TNBC patients to adjuvant chemotherapy treatment, while EGFR expression further characterize that response.

also in 53,322 other papers